After Bharat Biotech’s Covaxin, another potential COVID-19 vaccine indigenously developed by Ahmedabad-based Zydus Cadila Healthcare Ltd got nod from the Drugs Controller General of India (DCGI) on Thursday for human clinical trials, news agencies reported citing government sources said.
The move comes as a rapid response after recommendation by the topic expert committee as approved by DCGI.
The assent for human trials was given after the corporate submitted data of clinical test on animals to the DCGI, during which the vaccine candidate was found to achieve success with reference to safety and immunogenicity, sources said.
India has two indigenous manufacturers for the potential COVID-19 vaccine. within the recent past, DCGI has given permission to Bharat Biotech International Limited (BBIL), who has partnered with the Indian Council of Medical Research (ICMR) to conduct phase I clinical trial & II human clinical trials to develop an indigenous vaccine for COVID-19–in the name COVAXIN. The Bharat Biotech using the virus strain isolated at ICMR’s National Institute of Virology (NIV), Pune to develop the vaccine.
India’s COVID-19 tally rose to six ,04,641 on Thursday with a single-day increase of 19,148 cases, just five days after it crossed the five-lakh mark, while the price rose to 17,834 with 434 new fatalities, consistent with the Union Health Ministry.